Two oral GLP‑1 candidates reported mid‑stage efficacy that keeps the small‑molecule obesity race competitive with injectables. Structure Therapeutics reported placebo‑adjusted weight loss near double digits (~11.3%) at ~36 weeks in mid‑stage data but flagged high rates of nausea and vomiting during treatment. Separately, China’s Ascletis posted 7.7% placebo‑adjusted weight loss at 13 weeks in a U.S. phase 2 cohort and reported mostly grade 1–2 GI adverse events with weekly titration. The readouts underscore the tradeoff developers face between rapid weight loss and tolerability during dose escalation.